Open AccessReal-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
Author(s) -
Johannes Kleemann,
Martin Jäger,
Eva Maria Valesky,
Stefan Kippenberger,
Roland Kaufmann,
Markus Meißner
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s286917
Subject(s) - medicine , single center , adverse effect , retrospective cohort study , melanoma , population , progressive disease , surgery , disease , pediatrics , environmental health , cancer research
Rising melanoma incidences lead to an increasing need for individual therapy strategies in old patients. Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, approved for the local treatment of unresectable metastatic melanoma. Since data on the efficacy and safety of geriatric patients are sparse, this study was conducted to gain further real-world experience in the treatment of old and oldest-old patients with T-VEC and to obtain data on therapy costs in this population in Germany.